TORONTO--(BUSINESS WIRE)--Enigma Biomedical Group today announced a clinical research agreement with Austin Health in Melbourne, Australia to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
As part of the agreement, Enigma will provide funding for various research projects, and through its US entity Cerveau Technologies, Inc., will supply the MK-6240 precursor needed for the initiatives.
Lee Anne Gibbs, President of Enigma Biomedical Group said, “We are excited to partner with Austin Health. This is an important step in beginning a long-term relationship with Austin Health and a significant step towards establishing an international network to facilitate adoption of our technology and strategic initiatives."
Professor Christopher Rowe, Director of Molecular Imaging Research said, “These research projects will provide valuable insight into the status and progression of NFTs in healthy subjects, subjects with mild cognitive impairment and confirmed Alzheimer’s Disease. We appreciate the support of Enigma Biomedical Group and value our ongoing relationship.”
“At Cerveau, we are focused on providing information and technologies to researchers and clinicians to improve brain health,” said Rick Hiatt, President of Cerveau Technologies, Inc., and CEO of Enigma Biomedical Group, “We are excited by the opportunity to work with Austin Health in providing access to this novel imaging agent to the broader scientific community and in continuing our past working relationship with Prof. Rowe and Austin Health."
About Austin Health
Austin Health is an internationally recognized leader in clinical teaching and training. Austin LifeSciences brings together internationally renowned research institutes and over 800 Austin Health researchers. It is a world leader in the development and clinical application of imaging for dementia and has one of the largest dementia clinical trials sites in the world with over 30 trials currently recruiting. Austin Health is the lead imaging site for national multicenter dementia studies including the Australian Imaging Biomarkers and Lifestyle study of Aging (AIBL).
About Enigma Biomedical Group
Toronto based Enigma Biomedical Group (EBG) enhances access to key technologies with a focus on molecular imaging and medicine. EBG offers a suite of services to the pharmaceutical industry and clinical research community to accelerate drug development and global access. EBG partners with academic institutions and universities to foster and broaden access to novel research. More information can be found at http://www.enigmabiomedicalgroup.com/.
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.